You are here

Home » Reports

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 471 results
 
  • Record 1 TO 471

  1. LASH- Binocular Multispectral Adaptive Imaging System (BMAIS)

    SBC: Sage Technologies, Ltd.            Topic: AF083015

    Low Altitude Sensing Helmet -(LASH) is to provide for pilot night vision when using small non-military planes to operate using unimproved landing areas around the globe. LASH will use SWIR (Short Wave IR) and LWIR (Long Wave IR) technology sensors to provide improved night vision in specified conditions.

    SBIR Phase II 2019 Department of DefenseAir Force

  2. Novel Cannabinoid Receptor Agonists as Analgesics

    SBC: ADOLOR CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition that is undertreated because because of the dose-limiting side effects of currently used therapeutics. Agonists at the cannabinoid (CB) receptors, including delta-9-tetrahydrocannabinol, have been shown to relieve pain in humans, but their use has been limited due to their psychotr ...

    SBIR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health

  3. Discovery of K Opioid Analgesics Using Chimeric Receptor

    SBC: ADOLOR CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition that is under treated because of the dose limiting side effects of currently used opiate therapeutics including respiratory depression, constipation, nausea, and physical dependence at therapeutic doses. Although arylacetamide K opioid agonists do not cause these side effects, they produc ...

    SBIR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health

  4. Novel Antagonists of the ORL-1 Receptor

    SBC: ADOLOR CORPORATION            Topic: N/A

    N/A

    SBIR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health

  5. Novel Antagonists of the ORL-1 Receptor

    SBC: ADOLOR CORPORATION            Topic: N/A

    N/A

    SBIR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health

  6. Small Synthetic Aperture Radar (SmallSAR)

    SBC: Advanced Technologies/Laboratories Intl            Topic: N/A

    N/A

    SBIR Phase I 2001 Department of DefenseNavy

  7. Small Synthetic Aperture Radar (SmallSAR)

    SBC: Advanced Technologies/Laboratories Intl            Topic: N/A

    N/A

    SBIR Phase II 2001 Department of DefenseNavy

  8. Biocatalytic Polymer Skin Adhesives

    SBC: AGENTASE LLC            Topic: N/A

    This Phase II STTR proposal describes the development of a prototype enzyme-containing adhesive capable of attaching biocatalytic activity directly to skin. The adhesive, when containing organophosphorus-hydrolyzing enzymes, shall serve to protectunderlying skin from otherwise toxic applications of nerve agents and pesticides. Agentase, a recognized world leader in developing polymer-based carri ...

    STTR Phase II 2001 Department of DefenseArmy

  9. Biocatalytic Polymer Skin Adhesives

    SBC: AGENTASE LLC            Topic: N/A

    This Phase II STTR proposal describes the development of a prototype enzyme-containing adhesive capable of attaching biocatalytic activity directly to skin. The adhesive, when containing organophosphorus-hydrolyzing enzymes, shall serve to protectunderlying skin from otherwise toxic applications of nerve agents and pesticides. Agentase, a recognized world leader in developing polymer-based carri ...

    STTR Phase I 2001 Department of DefenseArmy

  10. PEG-MODIFIED ENZYMES FOR IN-VIVO DECON OF OP TOXINS

    SBC: AGENTASE LLC            Topic: N/A

    DESCRIPTION ( Investigator's Abstract): Agentase, LLC seeks Small Business Innovation Research funding to determine the feasibility of using chemically modified enzymes for the treatment and prevention of organophosphorus poisonings. Several known enzymes exhibit hydrolytic activity on target organophosphorus compounds including nerve agent, chemical weapons ...

    SBIR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government